CN108341797A

CN108341797A - A kind of novel synthesis of duloxetine intermediate

Info

Publication number: CN108341797A
Application number: CN201710055513.6A
Authority: CN
Inventors: 和国栋; 张风
Original assignee: Chongqing Chang Jie Pharmaceutical Co Ltd; Chongqing Shenghuaxi Pharmaceutical Co Ltd
Current assignee: Chongqing Chang Jie Pharmaceutical Co Ltd; Chongqing Shenghuaxi Pharmaceutical Co Ltd
Priority date: 2017-01-25
Filing date: 2017-01-25
Publication date: 2018-07-31
Anticipated expiration: 2037-01-25
Also published as: CN108341797B

Abstract

The present invention is a kind of 3 hydroxyl 3 (2 thienyl) 1_ propylamine of duloxetine intermediate (S) N methyl（Compound 1）Novel synthesis.The method is acylated using thiophene and succinic anhydride as raw material by Fu Ke, esterification, ammonolysis, asymmetric hydrogenation, and oxidative degradation obtains duloxetine intermediate（Compound 1）.

Description

A kind of novel synthesis of duloxetine intermediate

Technical field

The present invention relates to a kind of duloxetine intermediates（Compound 1）Synthetic method, belong to medicinal chemistry art.Chemical combination 1 structure of object is as follows：

Background technology

Duloxetine (Duloxetine) is a kind of antidepressants that Li Lai companies develop, and is a kind of serotonin and goes first Adrenaline reuptake inhibitor (SNRI) is listed in August, 2004 in the U.S..Duloxetine structure is as follows：

Duloxetine can inhibit neuron thus to improve both to the reuptake of serotonin and norepinephrine Concentration of the central neurotransmitter in brain and spinal cord, therefore Duloxetine can be used for treating certain mental state disease such as depression and coke Consider disease and alleviates central pain such as Diabetes Peripheral neuropathy pain and women's fibromyalgia etc..Duloxetine can also be made For the serotonin and norepinephrine receptor in urethra, to enhance sphincter urethrae neurogenic tonus degree and Contractility, so being treated to women's stress urinary incontinence disease also effective.Market potential is huge, is worth clinical and market concern.

Duloxetine and its preparation in United States Patent (USP) USP5023269 and USP4956388 and also have TetrahedronLetters, 31, (49) are described in 1990,7101-7104.In Drugs of theFuture It also reported seven kinds of different synthetic routes in 2000,25 (9) 907-916.These synthesize or are related to key intermediate It splits or is reduced into alcohol with being related to ketone group Stereoselective.

(S)-N- methyl -3- hydroxyls -3- (2- thienyls) -1_ propylamine（Compound 1）It is the key that in synthesis Duloxetine Mesosome.1 structure of compound is as follows：

Chemical resolution method is mostly used at present, and CN1747947 prepares I using chiral acid as resolving agent, and major defect exists It generally can only obtain one kind in enantiomer in chemical resolution, therefore, the theoretical yield highest of chemical resolution only has 50%, this is just Cause raw material availability low, at least the isomers of half can not recycle, and compound degree of recycling is relatively low, not meet green The requirement of colour chemistry and atom economy.

Asymmetric syntheses also sees prepare compound 1, and CN101104614 utilizes chiral catalyst asymmetry also its Central Plains carbonyl For base at hydroxyl, the chiral intermediate optical value that major defect is is low, and root is due to the methylamine based structures in molecule There are very strong complexing, world patent WO2008074858A1 and European patent EP 1506965A1 difference to hand-type catalyst Using different methods methylamino is carried out derivative and then achieves good effect carrying out asymmetry catalysis, but due to official The multistep conversion that can be rolled into a ball makes the tediously long industrial value of technique reduce.

Invention content

The present invention provides one kind (S)-N- methyl -3- hydroxyls -3- (2- thienyls) -1_ propylamine（Compound 1）System Preparation Method, raw material is cheap, high income, low in the pollution of the environment, and product quality is high.Synthetic route is as follows：

The preparation method of Duloxetine chiral intermediate of the present invention is passed through using thiophene and succinic anhydride as raw material Fu Ke is acylated, esterification, ammonolysis, asymmetric hydrogenation, and oxidative degradation obtains duloxetine intermediate（Compound 1）, specifically include with Lower step：

Step 1, it is condensed succinic anhydride and thiophene to form compound 2 under the action of alchlor, wherein solvent for use is lazy Property halogenated hydrocarbons, preferably dichloromethane.

Step 2, compound 2 and alcohol are converted to ester by the effect of catalyst, wherein used alcohol is to be containing carbon number The alcohol of 1-8 carbon straight chain or straight chain, wherein used catalyst is Bronsted acid or lewis acid, the preferably concentrated sulfuric acid.

Step 3, in solvent-free or atent solvent aminolysis is occurred into for compound 3 and methylamine and is converted into compound 4, wherein institute The solvent used is containing the alcohol that carbon number is 1-8 carbon straight chain or straight chain, preferred alcohol.

Step 4, compound 4 is added with hydrogen source under the co-catalysis of metallic catalyst and the ligand of hand-type containing phosphine in a solvent Pressure hydrogenation obtain optically pure compound 5, used in metallic catalyst be platinum metal salt or its complex, preferably 1,5- cyclo-octadiene radium chloride dimer.The ligand of hand-type containing phosphine therein is tertiary butyl Josiphos.And it has following structure：

Step 5, compound 5 is degraded to compound 1 under the action of oxidant in a solvent, used in oxidant For lead tetra-acetate and double trifluoroacetyl oxygroup iodobenzenes, preferably double trifluoroacetyl oxygroup iodobenzenes.

Compared with prior art, the invention has the advantages that：The present invention is simple and practicable, and the target product of preparation is received Rate is high, and optical purity is up to 99%, and purification difficulty is small, is suitble to amplification PRODUCTION TRAITS.

The present invention will be described for continuation by the following examples, is done according to ordinary skill knowledge and customary means The various replacements or combination gone out, should all be included within the scope of the invention.

Specific implementation mode

Chromatographic condition below is employed herein, raw materials used is commercial product:

HPLC chromatogram system A

HPLC chromatogram system B

Example 1

Thiophene 24ml and succinic anhydride 30g and dichloromethane 200ml is added in the there-necked flask of 500ml, stirs and is cooled to 0-5 DEG C, aluminum trichloride (anhydrous) 36g is added portionwise, is stirred at room temperature after charging 17 hours, reaction solution is then poured into 500ml's In trash ice, half an hour is stirred, organic layer is separated, organic layer is washed with 500ml clear water, is then evaporated, be added after magnesium sulfate drying The isopropyl ether stirred crystallization of 200ml filters, and solid 50-60 DEG C of forced air drying 12 hours under normal pressure obtain solid 44.7g, receive Rate 81%.

Example 2

100g compounds 2 are added in the there-necked flask of 500ml（Water content is less than 0.1%）, the dense sulphur of methanol and 10ml of 300ml Acid is heated to reflux 12 hours.Compound 2 is remaining to be less than 0.1%（Chromatographic system A）Stopped reaction afterwards.Air-distillation after reaction The methanol of recovery section, residue are cooled to room temperature, and 400ml dichloromethane and 500ml clear water is then added, and extraction layering has Machine layer washed once with the saturated sodium bicarbonate of 300ml, and dichloromethane layer drying is evaporated, yellow oil 101g, yield are obtained 94% is used directly for reacting in next step.

Example 3

100 compounds 3 obtained by upper step are added in the there-necked flask of 500ml, the methylethylolamine solution of 350ml is added, and 1g sodium ethoxides, are then warming up to 40-50 DEG C of insulation reaction 12 hours, and compound 3 is remaining to be less than 0.1%（Chromatographic system A）After stop Reaction solution is evaporated by reaction, vacuum distillation, and isopropanol 300ml is added into residue, after solid is precipitated, is cooled to 0-10 DEG C and is stirred It mixes 5 hours, filters, filter cake washs with 50ml isopropanols, and solid 50-60 DEG C of forced air drying 12 hours under normal pressure obtain solid 89g, yield 89.7%.

Example 4

60g compounds 4 are added into the stainless steel high-pressure hydrogenation kettle of 1L under nitrogen protection, add 1,5 cyclo-octadiene chlorinations Rhodium dimer 30mg and（R, S）Tertiary butyl Josiphos is eventually adding methanol 400ml, closes hydriding reactor, in nitrogen displacement kettle Gas 3 times, in 45-50 DEG C of hydrogenation 5 hours, is monitored with HPLC and is reacted then under the Hydrogen Vapor Pressure of 10kg, compound 4 Residue is less than 0.1%, rear stopped reaction（Chromatographic system A）.Reaction solution concentration is evaporated, is then added 200ml's into residue Methyl tertiary butyl ether(MTBE) is stirred at room temperature 1 hour, filters, and filter cake is washed with 50ml isopropanols, solid 50-60 DEG C of air blast under normal pressure It is 12 hours dry, solid 55g, yield 90.1% are obtained, HPLC purity is more than 97%, and optical purity is more than 98%ee（Chromatographic system B）.

Example 5

Compound 5 solid 10g and acetonitrile 40ml is added in the there-necked flask of 500ml, the water of 40ml is added after stirring and dissolving is limpid, Double trifluoroacetyl group iodobenzenes are added, the temperature of reaction solution is then raised to reflux 4 hours, compound 4 is remaining to be less than 0.1%, in rear Only react（Chromatographic system A）.It will be reacted in the ice water of 400ml, the pH value of solution be transferred to 8 to 9 with ammonium hydroxide, is added The dichloromethane of 200ml, extraction layering, dichloromethane layer are dried with magnesium sulfate, are concentrated to dryness, be added just into residue Hexane 90ml, at room temperature stirred crystallization 3, filter cake washed with 20ml n-hexanes, 40-50 DEG C of forced air drying 5 is small under normal pressure for solid When, solid 4.8g, yield 56% are obtained, HPLC purity is more than 96%, and optical purity is more than 99%ee（Chromatographic system B）.

Claims

1. a kind of duloxetine intermediate（Compound 1）Synthetic method,

It is characterized in that following steps：

1）Step 1, it is condensed succinic anhydride and thiophene to form compound 2 under the action of alchlor, wherein solvent for use is Inertia halogenated hydrocarbons, preferably dichloromethane；

2）Step 2, compound 2 and alcohol are converted to ester by the effect of catalyst, wherein it is 1-8 that used alcohol, which is containing carbon number, The alcohol of a carbon straight chain or straight chain, wherein used catalyst is Bronsted acid or lewis acid, the preferably concentrated sulfuric acid；

3）Step 3, in solvent-free or atent solvent aminolysis is occurred into for compound 3 and methylamine and is converted into compound 4, wherein used To solvent be containing the alcohol that carbon number is 1-8 carbon straight chain or straight chain, preferred alcohol；

4）Step 4, by compound 4 in a solvent with hydrogen source under the co-catalysis of metallic catalyst and the ligand of hand-type containing phosphine Pressure hydration obtains optically pure compound 5, used in metallic catalyst be platinum metal salt or its complex, it is excellent Select 1,5- cyclo-octadiene radium chloride dimers；The ligand of hand-type containing phosphine therein is tertiary butyl Josiphos；

5）Step 5, compound 5 is degraded to compound 1 under the action of oxidant in a solvent, used in oxidant be Lead tetra-acetate and double trifluoroacetyl oxygroup iodobenzenes, preferably double trifluoroacetyl oxygroup iodobenzenes.

2. according to claim 1, in step 4 compound 5 preparation method, it is characterized in that used hand-type containing phosphine ligand Ligand is（R, S）Tertiary butyl Josiphos, and have following structure：

。

3. according to claim 1, in step 5 compound 5 preparation method, it is characterized in that used oxidant is double three Acetyl fluoride oxygroup iodobenzene.